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Abstract Hypoxia stress plays a pivotal role in tumor forma-
tion, proliferation, and invasion. Conventional chemotherapy
is less effective in the hypoxia microenvironment of solid
tumor. Heat shock protein 90 (Hsp90) is an important molec-
ular chaperone in cancer cells and has been a pharmaceutical
target for decades. However, Hsp90 inhibitors demonstrate
limited effect on solid tumor and the mechanism underlying
is not clear. To determine whether hypoxia impairs the thera-
peutic effect of Hsp90 N-terminal inhibitor, 17-
demethoxygeldanamycin hydrochloride (17-DMAG), in live
cancer cells, we measured cell proliferation and cell cycle
distribution. Cell proliferation assay indicates that hypoxia
obviously promotes the proliferation of HepG2 and Huh7
cells after 24, 48, and 72 h and impairs 17-DMAG-induced
G2/M arrest in liver cancer cells. As a client protein of Hsp90,
cyclin B1 is critical for the transition from G2 to M phase and
is related to the prognosis of the patients. We further checked
the cyclin B1 messenger RNA (mRNA) level, protein level,
ubiquitination of cyclin B1, nuclear translocation, and degra-
dation of cyclin B1 affected by hypoxia after 17-DMAG treat-
ment. The results demonstrate that hypoxia decreases the
transcription of cyclin B1 and accelerates the ubiquitination,
nuclear translocation, and degradation of cyclin B1. Taken
together, our results suggest that hypoxia attenuates cyclin
B1 accumulation induced by 17-DMAG and, hence, alleviates
17-DMAG-induced G2/M arrest.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies and the second most frequent cause of cancer
mortality worldwide (Lin et al. 2012). According to 2014
Cancer Country Profiles from World Health Organization,
394,770 of new liver cancer cases and 380,772 cancer deaths
occurred in China. Besides China, the number of cases diag-
nosed with HCC is expected to increase in western countries
(Venook et al. 2010). In China, 5-year relative survival rate of
liver cancer is only 10.1 % (Zeng et al. 2015).
Identification of novel therapeutic agents via molecular
targeting offers the promise of treatment for advanced liver
cancer. However, the therapy targeted for one singlemolecular
faces the potential peril of being subverted by the inherent
genetic plasticity of cancer cells. Multiple molecular targets
have been used in combination, which are involved in a mul-
titude of signaling pathways leading to simultaneous adverse
effects on oncogenic proteins, would prove promising, but
also would make therapy more complicated and prolong the
trials (Patki and Pawar 2013; Isaacs et al. 2003).
Heat shock protein 90 (Hsp90), as an important member of
the heat shock protein family, is usually constitutively
expressed in most mammalian cell types and can be further
induced by heat shock and other stresses. Hsp90 plays a vital
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role in assisting more than 200 client proteins for their proper
folding, stability, and function (Patki and Pawar 2013). The
protein has been championed for over 20 years by the
National Cancer Institute (Bethesda, MD, USA) as a cancer
target since the discovery of the antitumor activity of the
natural product geldanamycin (Barrott and Haystead 2013).
So far, many kinds of Hsp90 inhibitors have been iden-
tified and many of them have already exhibited good
antitumor effects and have entered into different stage
of cl inical t r ia ls , such as geldanamycin (GA),
17-(allyamino)-17-demethoxygeldanamycin (17-AAG),
17-dimethylaminoethylamino-17-demethoxygeldanamycin
hydrochloride (17-DMAG), and so on. The crystal struc-
ture reveals that 17-DMAG binds to the ATP binding site
of Hsp90 N-terminal domain and is currently in phase I
clinical trials (Pacey et al. 2011). However, the therapeu-
tic effects vary in tumors, especially in solid tumor in-
cluding liver cancer, which presents poor response to
Hsp90 inhibitors.
Since the hypoxia microenvironment of the solid tumor
cells impairs the sensitivity to traditional chemotherapy, new
chemotherapies of liver cancer treatment are being sought.
Hypoxia is a characteristic of diverse human solid tumors,
including liver cancer, breast cancer, prostate cancer, and pan-
creatic cancer (Harrison and Blackwell 2004). especially, in
the processes of tumor growth. A rapidly growing tumor mass
quickly outstrips its vasculature and lacks oxygen and nutri-
ents. Although hypoxia is a harmful factor to the most of
normal cells and some tumor cells, it also provides a strong
selective pressure for the survival of the most aggressive and
metastatic cells (Yan et al. 2009). In fact, clinical studies have
clearly shown that there are two sides of the hypoxia. On one
hand, hypoxia induces unfolded protein response, cell death,
and the DNA damage response (DDR) (Olcina et al. 2010).
On the other hand, hypoxia is a plus factor to HCC. This
situation is therapeutically significant, as hypoxic cells are
more resistant to both chemotherapy and radiotherapy
(Black et al. 2015; Karakashev and Reginato 2015;
Horsman et al. 2012; Ghattass et al. 2013). In addition, hyp-
oxia promotes HCC invasion, metastasis (Yan et al. 2012).
and proliferation (Gwak et al. 2005).
Based on these previous studies of chemotherapy under
normoxia and hypoxia, we raised the hypothesis that hypoxia
could decrease the chemoresistance of HCC cells to 17-
DMAG. To test our hypothesis, we examined the effects of
normoxia or hypoxia on cell viability after 17-DMAG treat-
ment. We found that hypoxia counteracted 17-DMAG-
induced cell proliferation inhibition and attenuated the mitotic
blockage in G2/M with decreased cyclin B1.
Cyclin B1 is a client protein of Hsp90 and also a key pro-
tein in the control of cell cycle transition from G2 to M phase
(Ortiz et al. 2002). Deregulated expression of cyclin B1 may
induce a disrupted control of cell growth and a malignant
phenotype (Egloff et al. 2006; Chen et al. 2009). Hence, the
mechanism of the level change of cyclin B1 affected by hyp-
oxia and 17-DMAG treatment in HCC cells was further ex-
plored in this paper.
Materials and methods
Cell culture and reagents
Human liver cancer cell line HepG2 and Huh7 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
medium with 10 % fetal bovine serum (FBS), 100 units/ml
penicillin, and 100 μg/ml streptomycin. Normoxia or hypoxia
conditions were maintained at 37 °C in the incubator with
20 % O2 and 5 % CO2 or 95 % N2, 5 % CO2, and 1 % O2.
Hsp90 inhibitor 17-DMAG (Selleck, Houston, TX, USA),
anti-Hsp90α SPA840 (Enzo, Farmingdale, NY, USA), a
mouse anti-monoubiquitinylated and polyubiquitinylated con-
jugate antibody, clone FK2 (Merck Millipore, USA), a rabbit
anti-ubiquitin antibody Ub antibody (FL-76) (Santa Cruz,
USA), a rabbit anti-cyclin B1 antibody (H-20) (Santa Cruz,
USA), and the Cell Cycle Regulation Antibody Sampler Kit II
(CST, Danvers, MT, USA) were purchased. IRDye secondary
antibodies (Li-Cor, Lincoln, NE, USA) were used in the
experiments.
Cell viability assay
Cell viability was measured with a cell counting kit-8 (CCK8)
assay (Dojindo, Tabaru, Mashikimachi, Japan). Briefly,
HepG2 and Huh7 cells were seeded at a density of 2×103
cells per well in 96-well plates and incubated for 24 h. The
cells were treated with different concentrations of 17-DMAG
(0, 0.01, 0.05, 0.1, 0.5, 1, 5, 10 μM) in normoxia or hypoxia.
After the cells were incubated for 24 or 48 h, the CCK-8
solution was added to each well for another 2 h at 37 °C.
The absorbance was measured with a 96-well plate reader at
450 nm. Six replicate wells were included in each group.
Cell cycle analysis
Huh7 and HepG2 cells were incubated with 17-DMAG (0,
0.05, 0.1, 0.5, 1 μM) for 24 h under normoxia or hypoxia
condition. Cells were harvested and washed once in
phosphate-buffered saline (PBS). The resuspended cells were
added dropwise into a 15-ml conical tube containing 5 ml of
ice-cold 70 % ethanol while vortexing on medium speed.
Cells were kept at −20 °C overnight. Samples then were
washed with PBS and incubated with RNase and propidium
iodide solution for 30 min at 37 °C. The DNA content was
analyzed by GUAVA flow cytometry (Millipore, Billerica,
MA, USA). The percentage of cells in each phase of the cell
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cycle was determined by Mod fit LT 4.0 (Verity Software
House, Topsham, ME, USA).
Western blot analysis and co-IP
The cell lysis buffer consisted of 10 mM Na2HPO4, 1.8 mM
KH2PO4 pH 7.4, 137 mMNaCl, 2.7 mMKCl, 1 %Nonidet P-
40, 0.5 % deoxycholate, 0.3 % sodium dodecyl sulfate (SDS),
1 mM s o d i u m o r t h o v a n a d a t e , a n d 1 mM
phenylmethylsulfonyl fluoride. Protein concentrations of the
cell lysates were determined by the BCA method (Bio-Rad).
Each sample (40 μg) was separated by 10 % SDS-PAGE and
transferred onto a PVDF membrane. The membrane was
blocked in Tris-buffered saline (TBS) plus 5 % BSA for
90 min at room temperature and then incubated with primary
antibody in TBST plus 1 % BSA overnight at 4 °C. The
membrane was washed four times with TBST (TBS contain-
ing 0.1 % Tween 20) for 5 min each time at room temperature
and then incubated with IRDye 680/800 secondary antibody
for 60 min. After washing the membrane six times with TBST
for 5 min each time at room temperature, immunoreactive
bands were detected by Odyssey Infrared Imaging System
(Li-Cor, Lincoln, NE, USA).
For co-immunoprecipitation (co-IP), the proteins with pri-
mary antibody, a mouse anti-monoubiquitinylated and
polyubiquitinylated conjugate antibody, and clone FK2
(Merck Millipore, USA) were incubated in scroll oscillator
overnight at 4 °C; then, protein G agarose beads were added
to the mixtures and incubated for another 2 h. The agarose
beads were washed three times with cell lysis buffer and then
boiled with 2× SDS protein sample loading buffer for 10 min.
A rabbit anti-ubiquitin antibody Ub antibody (FL-76) (Santa
Cruz, USA) and rabbit anti-cyclin B1 antibody (H20) (Santa
Cruz, USA) were used for Western blot to avoid the inference
of mouse IgG heavy chain and light chain in this study.
Quantitative real-time reverse transcription polymerase
chain reaction assay
HepG2 and Huh7 cells were harvested in 35-mm dishes, and
RNA was isolated by TRIzol (Takara, Otsu, Shiga, Japan).
Five hundred nanograms of RNA was applied to synthesis
first-strand complementary DNA and using first-strand
cDNA Synthesis Kit (Takara, Otsu, Shiga, Japan). Reverse
transcription polymerase chain reaction (RT-PCR) was done
following the manufacturer’s instructions by Mx3000P Real-
Time PCR Detection System (Stratagene, Santa Clara, CA,
USA) with a mixture composed of SYBR Green (Takara,
Otsu, Shiga, Japan), 1 μl (0.2 μmol/l) of each primer, and
1.6 μl of complementary DNA from RT-PCR samples. The
pr imer sequences were as fo l lows: β -ac t in , 5 ′ -
TGGCACCACACCTTCTACAAT-3 ′ (forward), 5 ′-
AGAGGCGTACAGGGATAGCA-3′ (reverse); cyclin B1,
5′-ACCAAAATACCTACTGGGTCGG-3′ (forward), 5′-
GCATGAACCGATCAATAATGG-3′ (reverse). The level of
cyclin B1 messenger RNA (mRNA) was quantified by the Ct
values, andβ-actin was set as an internal control. Experiments
were performed in triplicate. The results were analyzed by the
ΔΔCT method.
Stable transfection of mCherry-cyclin B1 and time-lapse
imaging
With 20 μg plasmid DNA for the expression of cyclin B1-
mCherry wild-type (WT) (Addgene, Cambridge, MA, USA)
or empty control vector at 306 V, 975 μF, and 25.8 ms in 0.4-
cm electroporation cuvettes (Bio-Rad, Hercules, CA, USA)
by Gene Pulser II Electroporation System (Bio-Rad,
Hercules , CA, USA), 1 × 107 HepG2 cel l s were
electroporated. Selection was initiated 48 h after transfection
using 1000 μg/ml of G418 (Life Technologies, Grand Island,
NY, USA). The selection medium was changed every 2 days
for 4 weeks until all control cells died. Resistant single-cell
clones were isolated and digested under inverted fluorescent
microscopy and cultured for further identification.
HepG2 cells stably transfected with mCherry-cyclin B1
were seeded in 35-mm glass bottom dishes. After serum star-
vation for 24 h to achieve cell synchronization, cells were kept
at 0.5 μM 17-DMAG in DMEM medium with 10 % FBS at
37 °C in cell chamber supplied with mixed gas supply to
mimic normoxia condition (5 % CO2, 95 % air) or hypoxia
condition (1 % O2, 5 % CO2, 94 % N2), respectively. Time-
lapse images were obtained by Olympus FV1000 confocal
microscope (×40) (Olympus, Tokyo, Japan). The mCherry-
cyclin B1 images were obtained every 15 min for 24 h.
Quantifications for total and nuclear cyclin B1 were per-
formed using ImageJ software 1.48 (National Institutes of
Health, Bethesda, MD, USA). For cyclin B1 intensity mea-
surements, we used the following formulas: whole-cell
signal= sum of the intensity of the pixels for one cell; nucleus
signal= sum of the intensity of the pixels for nucleus portion;
cytoplasm signal= sum of the intensity of the pixels for one
cell− sum of the intensity of the pixels for nucleus; back-
ground signal=mean signal per pixel for a region selected just
beside the cell; whole-cell signal corrected=whole-cell signal
− (area for the selected cell×mean background); nucleus sig-
nal and cytoplasm signal were also corrected (Gavet and Pines
2010).
Statistical analysis
Results are presented as the mean± standard error of the mean
(SEM). Statistical analyses were performed using the
Student’s t test or one-way analysis of variance test with
SPSS 13.0 (IBM, Armonk, NY, USA). Graphs were generated
with Excel. P<0.05 was denoted as statistically significant.
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Results
Hypoxia promoted proliferation and chemoresistance
to Hsp90 inhibitor 17-DMAG in HCC cells
HepG2 and Huh7 cells were cultured under normoxia or
hypoxia condition. The effect of hypoxia treatment was
examined by HIF1α level (Fig. 1a). Cell proliferation assay
indicated that hypoxia obviously promoted the prolifera-
tion of HepG2 and Huh7 cells after 24, 48, and 72 h
(Fig. 1b). We then treated HepG2 and Huh7 cells with
different concentrations of 17-DMAG (0.01, 0.05, 0.1,
0.5, 1.0, 5.0, and 10 μM) for 24 h. As shown in Fig. 1c,
Hsp90 inhibitor 17-DMAG significantly inhibited cell pro-
liferation and was displayed in a concentration-dependent
manner. However, compared with normoxia, hypoxia
caused the decreased susceptibility to 17-DMAG, especial-
ly under a concentration of 1.0 μM. The calculated half-
maximal growth inhibition concentration (IC50) after 24-h
treatment of 17-DMAG was 0.51 vs. 0.31 μM (normoxia
vs. hypoxia) in HepG2 cells and was 0.89 vs. 0.76 μM
(normoxia vs. hypoxia) in Huh7 cells.
Fig. 1 Hypoxia promoted proliferation and chemoresistance to Hsp90
inhibitor 17-DMAG in hepatocellular carcinoma cells. HepG2 and Huh7
cells were grown under normoxia (20 % O2 and 5 % CO2, 37 °C) or
hypoxia (1 % O2, 5 % CO2, and 94 % N2, 37 °C). CCK-8 assay was
performed according to the manufacturer’s instruction. a Hypoxia effect
was confirmed by the increased level of HSF1. b Hypoxia promoted cell
proliferation both in HepG2 and in Huh7 cells. c The proliferative inhi-
bition effect of 17-DMAG onHepG2 andHuh7 cells under normoxia and
hypoxia after 24-h treatment with 17-DMAG. The inhibition rate was
significantly decreased under hypoxia. Data are presented as mean± SD
of three independent experiments (*p< 0.05, hypoxia vs. normoxia)
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Hsp90 inhibitor 17-DMAG induced cell cycle arrest
at G2/M phase and hypoxia attenuated the arrest
Previous studies have demonstrated that the Hsp90 inhibitor
17-DMAG induces the G2/M blockage in certain types of
human cancer cells (Watanabe et al. 2009). To investigate
whether hypoxia protects the cell from 17-DMAG-induced
G2/M blockages, cell cycle was examined after 24-h treatment
of 17-DMAG under normoxia or hypoxia. 17-DMAG in-
duced significant G2/M arrest under normoxia, but G2/M ar-
rest percentage was lower in hypoxia than normoxia (Fig. 2).
Under 17-DMAG concentrations of 0.1, 0.5, and 1.0 μM,
HepG2 cells presented the lower G2/M arrest under hypoxia,
compared with normoxia (Fig. 2a). Huh7 (Fig. 2b) presented
the G2/M arrest inhibition under hypoxia, and with the in-
crease of the concentration of 17-DMAG, from 0.05 to
0.5 μM, the difference (P<0.05) of G2/M arrest between
normoxia and hypoxia decreased. Only under 1 μM of 17-
DMAG was the difference between normoxia and hypoxia
diminished.
17-DMAG induced the increasing level of cyclin B1,
but hypoxia attenuated the increase
To further explore the mechanism of hypoxia-attenuated G2/
M cell cycle arrest induced by 17-DMAG, we detected the cell
cycle-related protein, cyclin B1, and p-histone (Ser10), which
increased during G2/M phase (Fig. 3a). 17-DMAG treatment
Fig. 2 Hypoxia alleviated 17-DMAG-induced G2/M arrest. Liver cancer
cell line HepG2 (a) and HuH7 (b) were treated with increasing concen-
trations of 17-DMAG (0, 0.05, 0.1, 0.5, 1 μM) for 24 h. Cell cycle
distribution was analyzed with flow cytometry. Assays were performed
in triplicate. 17-DMAG-induced G2/M arrest was more obvious in
normoxia than hypoxia under 0.05, 0.1, and 0.5 μM in both cell lines,
except 1 μM 17-DMAG-induced similar G2/M arrest of HuH7 cells in
normoxia and hypoxia condition. Data are presented as mean ± SD of
three independent experiments (*p < 0.05, hypoxia vs. normoxia)
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under normoxia increased the level of cyclin B1 and p-
Histon3 (Ser10).Meanwhile, comparedwith normoxia, cyclin
B1 and p-histone 3 (Ser10) induced by 17-DMAGwere lower
in hypoxia (Fig. 3b), which is consistent with the G2/M phase
changes determined by flow cytometry.
Hypoxia inhibited transcription of cyclin B1
and accelerated ubiquitination of cyclin B1
The dynamic change of cyclin B1 includes the delicate bal-
ance of synthesis and degradation, which is important for the
cell cycle transition from G2 to M. Cyclin B1 begins to accu-
mulate in the S phase and is localized in the cytoplasm, then
reaches the maximal level at mitosis, and is imported into
nucleus where it will be rapidly degraded at the meta-phase-
anaphase transition (Smits and Medema 2001; Nimeus-
Malmstrom et al. 2010).
To determine why cyclin B1 decreased under hypoxia, we
detected the cyclin B1 mRNA by real-time semiquantitative
reverse transcriptase (RT-PCR). RT-PCR was used to deter-
mine whether decreased cyclin B1 was due to decreased tran-
scription of cyclin B1 mRNA after 24-h exposure to hypoxia.
As shown in Fig. 4a, although cyclin B1 mRNA level in-
creased significantly when treated with 17-DMAG (0.05,
0.5 μM) under normoxia for 24 h, cyclin B1 mRNA level
slightly increased under hypoxia.
Since the impairment of degradation of cyclin B1could also
be contributed to cyclin B1 accumulation, the ubiquitination
of cyclin B1 after 17-DMAG treatment was detected (Fig. 4b).
These results indicate that 17-DMAG treatment inhibited the
ubiquitination of cyclin B1 under normoxia and that hypoxia
Fig. 2 (continued)
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abrogated the decreased ubiquitination of cyclin B1 caused by
17-DMAG treatment.
Hypoxia accelerated the decrease of total cyclin B1 level
and the translocation of cyclin B1 into nucleus
To further explore the degradation and translocalization of
cyclin B1 induced by hypoxia, we recorded the time-lapse
images in HepG2 cells transfected with plasmid of
mCherry-cyclin B1 by confocal microscopy for 24 h. The
exogenous mCherry-tagged cyclin B1 was used to monitor
the degradation of cyclin B1 under different treatments.
Single-cell clone stably transfected with mCherry-cyclin
B1 was confirmed by Western blotting (Fig. 5a). The re-
sults showed that exogenous mCherry-cyclin B1 accumu-
lated more obviously under normoxia in comparison with
hypoxia (Fig. 5b). Furthermore, HepG2 cells under
normoxia took longer (16 h) to translocate and accumulate
cyclin B1 into nucleus than hypoxia (8 h). Cyclin B1 rap-
idly degraded when cyclin B1 translocated from cytoplasm
Fig. 4 Hypoxia inhibited transcription of cyclin B1 and accelerated
ubiquitination of cyclin B1. a The mRNA levels of cyclinB1 in HepG2
cells under normoxia or hypoxia condition for 24 h were determined by
real-time PCR assay. Each experiment was done three separate times
(bars , SD; *p < 0.05). b Ubiquitinated cyclin B1 was co-
immunoprecipitated with mouse anti-ubiquitin antibody and probed with
rabbit anti-cyclin B1 and rabbit anti-ubiquitin antibody. 17-DMAG treat-
ment inhibited the ubiquitination of cyclin B1, and hypoxia abrogated the
inhibition of cyclin B1 ubiquitination with 17-DMAG treatment
Fig. 3 Hypoxia attenuated the 17-DMAG-induced cyclinB1 accumula-
tion. HepG2 and Huh7 cells were incubated with 17-DMAG at different
concentrations for 24 h. a Protein extracts were analyzed by immunoblots
for cyclin B1 and p-histone 3 (Ser 10). b The intensities of cyclin B1
bandswere analyzed by ImageJ. Data are presented asmean ± SD of three
independent experiments (*p< 0.05, hypoxia vs. normoxia)
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to the nucleus, which indicted the beginning of mitosis. The
time-lapse recording of cyclin B1 intensity was presented
by three cells of each normoxia or hypoxia group (Fig. 5c)
for total cyclin B1 level (Fig. 5c, upper panel) or nuclear
cyclin B1 level (Fig. 5c, lower panel). The changes in the
curves indicate that hypoxia accelerated time course for the
decrease of total cyclin B1 level and the translocation of
cyclin B1 into nucleus.
Discussion
Most cancer cells have deregulated G1 checkpoints making
them dependent on their S and G2 checkpoints, so S and G2
checkpoints become an attractive target therapy of cancer
(Chen et al. 2012). 17-AAG abrogates hepatocellular cancer
growth through G2/M cell cycle arrest (Watanabe et al. 2009).
17-DMAG is a water-soluble analogue of 17-AAG (Kummar
Fig. 5 Hypoxia accelerated nuclear import and consequential
degradation of cyclinB1. a HepG2 cells expressing cyclin B1-mCherry
were checked by Western blot. b HepG2 cells were synchronized by
serum starvation and kept in a cell chamber to mimic normoxia or hyp-
oxia condition. The images were captured every 15 min by time-lapse
florescence microscopy. One cell entering mitosis under normoxia or
hypoxia treatment is displayed. The results showed that exogenous
mCherry-cyclin B1 accumulatedmore obviously under normoxia in com-
parison with hypoxia. Furthermore, HepG2 cells under normoxia took
longer time (16 h) to translocate and accumulate cyclin B1 into nucleus
than hypoxia (8 h). Cyclin B1 rapidly degraded when cyclin B1
translocated from cytoplasm to the nucleus, which indicated the begin-
ning of mitosis. c The time-lapse recording of cyclin B1 intensity was
presented by three cells of each normoxia or hypoxia group for total
cyclin B1 level (upper panel) or nuclear cyclin B1 level (c, lower panel).
The experiments about the cyclin B1 nuclear translocation were repeated
three times, and the similar results were observed. The three cells were
from the same experiment to minimize the discrepancy caused by differ-
ent experiments. The changes in the curves indicate that hypoxia accel-
erated time course for the decrease of total cyclin B1 level and the trans-
location of cyclin B1 into nucleus
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et al. 2010), and our results show that hypoxia decreases the
chemosensitivity to 17-DMAG and attenuates 17-DMAG-
induced G2/M arrest, with lower cyclin B1 level.
Hypoxia in tumors is associated with selection of geno-
types favoring survival and pro-survival changes in gene ex-
pression and gain resistance to chemotherapy (Wilson and
Hay 2011; Dong et al. 2012). Many genetic abnormalities
have been revealed in tumor cells and altered expression of
cell cycle regulators like cyclin D1 and cyclin-dependent ki-
nase (CDKs). Cyclin B1may be related to the prognosis of the
patients, though the evidences are still controversial. The oc-
currence, development, and treatment of cancer may also be
related to cyclin B1. Deregulated expression of cyclin B1 may
lead to a disrupted control of cell growth and a malignant
phenotype (Egloff et al. 2006; Chen et al. 2009). Abundance
of cyclin B1 (Porter et al. 2000) and increased expression of
cyclin B1 (Gomez et al. 2007) are parallel to better prognosis.
As a client protein of Hsp90, cyclin B1 is critical for the
transition from G2 toM phase. The main function of Hsp90 is
to help the folding of the denatured client proteins, and the
inhibition of Hsp90 will induce the degradation of the client
proteins. However, the client protein of Hsp90, cyclin B1,
slightly increased in presence of Hsp90 inhibitor
geldanamycin (GA) or in Hsp90 mutants, and Hsp90α is crit-
ical for the precise localization of cyclin B1 to the mitotic
spindle in Drosophila and human cells (Basto et al. 2007).
Also, treatment with Hsp90 inhibitors or heat shock induced
an increasing mRNA level of cyclin B1 and the accumulation
of cyclin B1 (Watanabe et al. 2009; Burrows et al. 2004). All
these indicate that Hsp90 might also be involved into the cell
cycle control of tumor cells and, by regulation, the level of
cyclin B1. And, then what is the relevance between
chemoresistance and cyclin B1? In our research, the results
suggest that 17-DMAG induces accumulation of cyclin B1
and inhibits tumor cell proliferation. Meanwhile, hypoxia im-
pairs the 17-DMAG-induced proliferation inhibition with
lower cyclin B1 level through inhibiting cyclin B1 mRNA
transcription and accelerating cyclin B1 nuclear translocation
and degradation. Since cyclin B1 nuclear translocation and
degradation are critical for G2/M transition and cell division,
decreased cyclin B1 level could be tightly related to hypoxia-
induced chemoresistance to 17-DMAG.
Our research provides a possible mechanism of hypoxia-
induced chemoresistance in liver tumor, and the decrease level
of cyclin B1 coordinates with the chemoresistance to Hsp90
inhibitor 17-DMAG under hypoxia. Since the presence of a
quinone of 17-DMAG makes it uniquely redox sensitive
(Samuni et al. 2010). How much does it contribute to
hypoxia-induced chemoresistance in liver tumor? How does
hypoxia inhibit cyclin B1 level? Is it caused by hypoxia-
induced DNA damage and genotype adaptation? All these still
need to be further explored with other Hsp90 inhibitors in
different liver tumor cell lines and in vivo experiments.
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